CSVT is an important complication of childhood ALL therapy. Postinduction combined asparaginase and dexamethasone intensive treatment for intermediate-/high-risk patients was the most important risk factor. Treatment with LMWH for a minimum of 3 months, and until asparginase therapy is over, with major radiological improvement seems to be effective and feasible.

With modern risk-adapted therapy, over 80% of children with acute lymphoblastic leukemia (ALL) in highincome countries (HICs) are cured. In countries with limited resources, however, therapy results for pediatric ALL are still not encouraging. We describe our experience in treating children with ALL using a risk-adapted protocol at a tertiary referral center in Lebanon. From May 2002 to August 2009, 111 consecutive patients 1-21 years of age with newly diagnosed ALL received the CCCL ALL protocol which was based on the St. Jude Children's Research Hospital Total XV Study. The median age at diagnosis was 5 years 5 months. The male to female ratio was 1.5. Forty-six patients received the intermediate-/high-risk arm and 65 received the low-risk arm. Only one patient (0.9%) died during induction therapy. Relapse occurred in 8 (7.2%) patients. Eight (7.2%) patients died, 4 of whom were in remission. The median follow-up of the patients was 38 months. The 5-year overall survival and event-free survival were and 88.5% (95% CI: 77.1-94.4) and 78.7% (95% CI: 69.8-88.4), respectively. Our results are comparable to those in HICs in spite of the limited resources and the relatively low socioeconomic status of the Lebanese population. Children treated on this protocol experienced significant toxicity necessitating expert supportive care, but benefited from improved cure rates and prolonged survival. Am. J. Hematol. 87:678-683, 2012. V

The incidence of symptomatic venous thromboembolism (VTE) in children receiving therapy for acute lymphoblastic leukemia (ALL) varies widely and is protocol dependent. The authors herein report the incidence and potential risk factors for VTE in children with ALL while being treated on a uniform protocol at a single tertiary care center in Lebanon. The authors also examine necessary modifications in a recently published model before it could predict VTE in their patients.

We herein describe a 16-year-old child with acute lymphoblastic leukemia and acute pancreatitis who developed Wernicke's encephalopathy secondary to prolonged total parenteral nutrition (TPN) that lacked vitamin B1 supplementation. The patient showed a direct and complete response to thiamine therapy. Diagnostic challenges are discussed and recommendations for prophylactic vitamin B1 supplementation in children with leukemia who are placed on TPN are made.

876 Background: Acute lymphoblastic leukemia (ALL) represents about 25% of all pediatric cancers. With modern risk adapted therapy over 80% of children with ALL are cured in developed countries. In countries with limited resources, however, therapy results for pediatric ALL are still not encouraging. We herein describe our experience in adopting an aggressive ALL protocol and the results and complications of using this risk-adapted protocol for treating children with ALL at a tertiary referral center in Lebanon. Patients: From May 2002 to August 2009, 110 consecutive patients 1–21 years of age with newly diagnosed ALL received the CCCL ALL protocol which was based on the St. Jude Children's Research Hospital Total XV Study. Patients were classified into one of three categories: low, standard, or high risk. Results: The clinical and laboratory characteristics of patients are presented in Table 1. The median age at diagnosis was 5 years 5 months. The male to female ratio was 1.5. Forty-six patients received the standard/high risk arm and 64 received the low risk arm. One patient (0.91%) died during induction therapy. Relapse occurred in 7 (6.4%) patients; 2 patients with T-cell ALL and WBC count >100 × 109/L developed CNS relapse during maintenance therapy, and 5 patients developed bone marrow relapse. During induction chemotherapy, patients had the following complications: 17 (15.4%) patients developed febrile neutropenia, 12 diarrhea, 6 tumor lysis syndrome, 1 typhlitis, 2 SIADH, and 2 hypertension. In addition, one patient had nasal septal aspergillosis, 1 influenza A infection, 2 sinusitis, 4 extremity cellulitis, 1 orbital cellulitis, 3 thrombosis (1 femoral line and 2 extremity). Complications during consolidation and maintenance included fever and neutropenia, pneumonia, recurrent otitis media, sinusitis, cellulitis of the face, herpes zoster, diarrhea, as well as gram positive and gram negative septicemia. Two patients died of Escherichia coli (ESBL) septic shock. Cytomegalovirus (CMV) retinitis was diagnosed in 4 patients; all were treated with gancyclovir. One patient developed PML (progressive multi-focal leukoencephalopathy). Three patients developed PRES (posterior reversible encephalopathy syndrome). Five patients developed sagittal sinus thrombosis and 5 developed pancreatitis secondary to L-asparaginase. Eight (7.3%) patients died, 4 (3.6%) of whom were in remission. None of the patients developed a secondary malignancy. The median follow up of the patients was 37.7 months (range 1.7–89.3) and the estimated mean survival time was 82.4 months (95% CI: 77.8–87.0). The 5-year overall survival and event-free survival were and 88.4% and 79.5%, respectively (Figure 1 & 2). Conclusions: Our results are comparable to those in developed countries in spite of the limited resources and the relatively low socioeconomic status of the Lebanese population. This treatment protocol was effective in improving the survival rates of children with ALL at our institution. Despite the fact that we had significant toxicity, there was a great advance in outcome reflected in the prolonged survival and improved cure rates. An aggressive risk stratified ALL protocol may be implemented successfully in a developing country but the toxicity profile may be completely different and more severe compared to that of developed countries. Disclosures: Muwakkit: Children's Cancer Center of Lebanon: Research Funding.